Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by lonc17on Feb 27, 2024 2:08pm
95 Views
Post# 35901965

RE:RE:RE:RE:RE:RE:RE:RE:Very strange , even for ONC

RE:RE:RE:RE:RE:RE:RE:RE:Very strange , even for ONC
Andrew exercised his options because he knew he was jumping ship and he would then be able to sell the shares for a profit without having to disclose to SEDI, since he was no longer an insider. Had he remained U.S. president of Oncolytics he would likely have taken the same route as MC (see below), becuase it would have been bad optics for him to exercise and sell.

MC absolutely DID NOT exercise his options. Please understand that Canadafan can sometimes say things that are demonstratably false but he phrases it in a manner such as, \
"I heard..."
"Not sure, but..."
"Different sources say... "

MC did not exercise his options because he knew that ONC had no good news coming and he expected the SP to drop to the same level as his exercise price (it did). This would be equivalent to him using some of his massive salary to buy ONC shares on the open market, which he has never done before and never will do because ONC is a bad investment.

Canadafan, are we supposed to feel sorry for some clown who ranks as one of the worst CEO's in biotech, yet makes almost $1 million per year and rewards himself with hundreds of thousands of options approved by a friendly BOD?

Give me a break!


<< Previous
Bullboard Posts
Next >>